Matrix Therapy Company
in Regenerative Medicine
Bringing
Matrix Therapy
from research
to patients
We are a clinical-stage regenerative medical device company developing novel matrix therapies to improve the lives of patients suffering from dermatological and neurological diseases with large unmet medical needs.
The RGTA®
Technology
ReGeneraTing Agents (RGTA®) help restore the natural micro-environment around cells, promoting tissue regeneration.
Research & Development
OTR3® is a biotechnology company with a strong lead in Research and Development, which excellence has been recognized by the European Commission (SME H2020 Instrument) and the French National Research Agency (ANR).
Our Lead Product
Cacipliq 20® is the first therapeutic product based on the innovative RGTA® technology.
Cacipliq 20 ®
This CE marked medical device promotes natural skin regeneration. Cacipliq 20® is intended to improve the healing of chronic cutaneous ulcers.
